23andMe logo

Computational Target Biology Summer Intern (Remote) - 23andMe

View Company Profile
Job Title
Computational Target Biology Summer Intern (Remote)
Job Location
South San Francisco, CA
Job Description

During our 10-week summer internship program, you’ll join our Therapeutics - Computational Biology team who work on understanding if a genetic variation can cause or contribute to the pathogenesis of a disease and predicting if a pharmacological intervention would be successful in improving the outcome. You’ll have the opportunity to develop skills such as contributing to the innovative drug development pipeline in a corporate setting. The dates for Cohort 1 will be June 5, 2023 - August 18, 2023; the dates for Cohort 2 will be June 20, 2023 - September 1, 2023.

 

Who We Are

Since 2006, 23andMe’s mission has been to help people access, understand, and benefit from the human genome. We are a group of passionate individuals pushing the boundaries of what’s possible to help turn genetic insight into better health and personal understanding.

 

What You'll Do

  • Help develop methods aimed at identifying pathogenic molecular mechanism that are shared across different disease or traits for clusters of GWAS signal to help elucidate how loci mediate the relationships with phenotypes
  • Implement or extend the use of software tools and pipelines for omics data, particularly single-cell and bulk RNA-seq as well as spatial transcriptomics
  • Learn how to work in a highly regulated industrial environment
  • Learn about and contribute to the innovative drug development pipeline at 23andMe by completing a project
  • Interact with other 23andMe scientists through your project, team meetings and seminars, and learn about the wide variety of research at 23andMe

 

What You'll Bring

  • Currently pursuing a Master or PhD degree in Computational Biology, Bioinformatics, Statistical Genetics, Computer Science or Statistics
  • Experience in Python and/or R programming 
  • Experience in analyzing genetic and genomic data
  • Authorization to work in the US
Please share with us why you're interested in this opportunity in a cover letter!
 

About Us

23andMe, headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80 percent of its customers electing to participate. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas. More information is available at www.23andMe.com.

At 23andMe, we value a diverse, inclusive workforce and we provide equal employment opportunity for all applicants and employees. All qualified applicants for employment will be considered without regard to an individual’s race, color, sex, gender identity, gender expression, religion, age, national origin or ancestry, citizenship, physical or mental disability, medical condition, family care status, marital status, domestic partner status, sexual orientation, genetic information, military or veteran status, or any other basis protected by federal, state or local laws.  If you are unable to submit your application because of incompatible assistive technology or a disability, please contact us at accommodations-ext@23andme.com. 23andMe will reasonably accommodate qualified individuals with disabilities to the extent required by applicable law.

Please note: 23andMe does not accept agency resumes and we are not responsible for any fees related to unsolicited resumes. Thank you.

23andMe Headquarters Location

Mountain View, CA

23andMe Company Size

Between 500 - 1,000 employees

23andMe Founded Year

2006

23andMe Funding Rounds

  • Post Ipo Equity

    $250,000,000 USD

  • Series F

    $82,500,000 USD

  • Corporate Round

    $300,000,000 USD

  • Series F

    $250,000,000 USD

  • Grant

    $1,700,000 USD

  • Series E

    $115,000,000 USD

  • Grant

    $1,400,000 USD

  • Series D

    $50,000,000 USD

  • Series C

    $9,000,000 USD

  • Series C

    $22,220,289 USD

  • Series B

    $14,200,000 USD

  • Series B

    $13,600,000 USD

  • Series A

    $8,953,320 USD